Lancet correspondence argues for personalised maintenance after tirzepatide weight loss
Van Bruggen, Damhof and colleagues address what happens to patients once the active weight-loss phase of tirzepatide treatment ends.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 9 07:00 ETSource: Lancet (London, England)
The wire
- 01A correspondence piece in The Lancet, dated 10 October 2026, takes up how maintenance therapy should be individualised after weight loss on tirzepatide.
- 02Maintenance strategy is a live question for prescribers managing weight regain and long-term cost once patients reach a plateau on an incretin agent.
- 03The item is correspondence rather than trial data, so it carries no new outcomes and its recommendations remain the authors' interpretation.
From the source
Read at pubmed.ncbi.nlm.nih.govPersonalising maintenance after tirzepatide weight loss
Lancet (London, England) · 2026 Oct 10 · van Bruggen FH, Damhof MA et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42849469/
